Sensitive skin fading and relieving composition as well as preparation method and application thereof

Abstract

The invention relates to a sensitive skin red fading and relieving composition as well as a preparation method and application thereof. The sensitive skin red fading and relieving composition comprises the following components: stachyose, silk fibroin, glycosylglycerol, 4-tert-butyl cyclohexanol and a flaxseed extract. The weight ratio of the stachyose to the silk fibroin to the glycosylglycerol to the 4-tert-butyl cyclohexanol to the flaxseed extract is (0.5 to 8): (0.01 to 2): (0.01 to 1): (0.01 to 1): (0.01 to 1). The composition disclosed by the invention can achieve a good soothing effect through multi-target-point synergism, and has high efficiency and safety at the same time.

Description

Technical Field

[0001] This invention relates to the technical field of cosmetics, specifically to a soothing composition for reducing redness in sensitive skin, its preparation method, and its application. Background Technology

[0002] Skin sensitivity and redness are the result of multiple pathophysiological processes, primarily involving three mechanisms: 1. Vascular response: External stimuli or internal factors cause dilation of skin capillaries and increased blood flow, resulting in visible redness; 2. Inflammatory response: Irritants activate immune cells to release inflammatory mediators such as histamine, prostaglandins, and leukotrienes, leading to increased vascular permeability, redness, swelling, and a burning sensation; 3. Neurogenic stimulation: Abnormal activation of sensory nerve endings (such as transient receptor potential vanillic acid subtype 1, TRPV1) leads to the release of neuropeptides (such as substance P), further exacerbating vasodilation and inflammatory responses, forming "neurogenic inflammation." These three pathways often intertwine and amplify, leaving the skin in a hyperreactive state that is difficult to alleviate effectively through a single pathway.

[0003] Currently, soothing technologies for sensitive and red skin mostly focus on single or limited mechanisms. For example, classic anti-inflammatory ingredients such as dipotassium glycyrrhizate and bisabolol primarily inhibit inflammatory mediators; some skincare products use physical cooling or astringents (such as zinc sulfate) to temporarily constrict blood vessels; and in recent years, neuromodulatory ingredients such as acetyl dipeptide-1 cetyl ester or certain synthetic molecules have begun to be used. However, existing technologies generally have limitations: first, single-target ingredients cannot fully cover the complex network of blood vessels, inflammation, and nerves, resulting in limited overall soothing effects; second, some anti-inflammatory ingredients have slow onset of action or poor stability; third, some synthetic soothing agents may be accompanied by potential irritation or insufficient long-term safety data; and finally, most solutions lack simultaneous repair of the skin barrier function, failing to reduce skin sensitivity at its root. Therefore, the market urgently needs a soothing composition that can target multiple points synergistically, and combines high efficacy with safety. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and provide a sensitive skin redness-relieving and soothing composition, its preparation method, and its application.

[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a sensitive skin redness-relieving and soothing composition comprising the following components: stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract, wherein the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract is (0.5-8):(0.01-2):(0.01-1):(0.01-1):(0.01-1).

[0006] The specific functions of each component in the composition are as follows: The stachyose is an oligotetraglucan composed of galactobiose, glucose, and fructose, naturally found in plants such as those in the genus Stachys, and has skin moisturizing and soothing effects, helping to maintain the integrity of the skin barrier. The silk fibroin is a natural high-molecular-weight fibrous protein derived from silk, which strengthens the skin's physical barrier by forming a film to block irritants. The glyceryl glucoside is a sugar derivative moisturizer and the main active ingredient of Myrothamnus flabellifolia (resurrection plant), which can protect cells from damage caused by harsh external environments and improve skin dryness and sensitivity. The 4-tert-butylcyclohexanol can effectively inhibit the pain receptor TRPV1, thereby soothing nerve sensitivity and reducing skin redness and irritation. The flaxseed extract is a natural ingredient extracted from flaxseed, rich in linolenic acid, linoleic acid, and flaxseed cyclic peptides, which has anti-inflammatory and antioxidant effects, while also helping to enhance the skin barrier function.

[0007] Preferably, the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract is (1-5):(0.1-1):(0.1-0.5):(0.05-0.5):(0.05-0.5).

[0008] More preferably, the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract is (2-3):(0.3-0.5):(0.2-0.3):(0.1-0.2):(0.1-0.2).

[0009] In a second aspect, the present invention provides the application of the sensitive skin redness-reducing and soothing composition described in the first aspect in the preparation of cosmetics.

[0010] Preferably, the cosmetic is a toner, lotion, cream, mask, serum, or spray, and the amount of the composition added is 1%-5% of the total weight of the cosmetic.

[0011] Thirdly, the present invention provides a lotion with soothing and repairing effects, comprising the following ingredients by weight percentage: 1%-5% of the sensitive skin redness-reducing and soothing composition described in the first aspect, 0.1%-0.3% of a thickener, 0.5%-2.5% of a moisturizer, 3-5% of an oil phase and 0.01%-0.3% of a pH adjuster, with the balance being deionized water.

[0012] Preferably, the thickener comprises at least one of xanthan gum, carbomer, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer and ammonium acryloyldimethyl taurate / VP copolymer.

[0013] Preferably, the moisturizer comprises at least one of allantoin, hydrogenated lecithin, betaine, β-glucan, trehalose, caprylyl glycol, dipropylene glycol, sodium hyaluronate, 1,2-butanediol, and glycerin.

[0014] Preferably, the oil phase is a composition of C14-22 alcohol, C12-20 alkyl glucoside, and caprylic / capric triglyceride.

[0015] Preferably, the pH adjuster includes at least one of arginine, sodium hydroxide, and disodium EDTA.

[0016] Fourthly, the present invention provides a method for preparing the emulsion of the third aspect, comprising the following steps: S1. Mix the humectant, thickener, deionized water and part of the pH adjuster, and homogenize at 75-85℃ to obtain phase A; S2. Heat the oil phase to 70-80℃ and homogenize it to obtain phase B; S3. Heat phase A to 75-85℃ and mix it with phase B. When the system cools down to 35-45℃, add each component of the sensitive skin redness relief and soothing composition and stir evenly. Finally, add the remaining pH adjuster to adjust the pH to obtain the emulsion.

[0017] Compared with the prior art, the beneficial effects of the present invention are as follows: The composition of this invention utilizes five carefully selected components—stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol, and flaxseed extract—to construct a multi-target synergistic system: 4-tert-butylcyclohexanol rapidly inhibits the neurotransmitter receptor (TRPV1) for immediate redness reduction; flaxseed extract and stachyose synergistically inhibit inflammatory mediators, reducing deep redness and swelling; silk fibroin and glyceryl glucoside powerfully repair and moisturize, strengthening the skin barrier. This composition simultaneously acts on four key pathways: nerve conduction, inflammatory response, vasodilation, and barrier repair, thus achieving the dual advantages of immediate relief from burning redness and long-term improvement of skin redness and sensitivity. Furthermore, all components are designed for gentleness and low irritation, making it especially suitable for sensitive skin. Attached Figure Description

[0018] Figure 1 This is a comparison image of the facial red area between Example 1 and the blank application example in Test Example 4. Detailed Implementation

[0019] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0020] The sources of the raw materials used in the following examples and comparative examples are as follows: Stachyose: Manufacturer is Xi'an Weisbo Biotechnology Co., Ltd., product number is WSB-SST; Silk fibroin: Manufacturer is Tianben Biotechnology (Shanxi) Co., Ltd., product number is tb-0625-035; 4-tert-Butylcyclohexanol: Manufacturer: Wuhan Chengtian Fine Chemical Co., Ltd., Product No.: 98-52-2; Glyceryl glucoside: Manufacturer: Xi'an Zhengte Biomedical Technology Co., Ltd., Product No.: zt2025031721; Flaxseed extract: Manufacturer is Shaanxi Bai'ao Biotechnology Co., Ltd., product number is BA-YMZTQW; Fructooligosaccharides: Manufacturer: Xi'an Sosite Biotechnology Co., Ltd., Product No.: SOST-257; Mussel adhesive protein: Manufacturer: Qinhe Health Industry (Shaanxi) Co., Ltd., Product No.: QH-24021905; Aminomethylpropanol: Manufacturer: Wuhan Lanabai Pharmaceutical Chemical Co., Ltd., Product No.: DW3432; Glycerin: Manufacturer is Guangdong Jihe New Materials Co., Ltd., product number 20251219; Grape seed extract: Manufacturer: Shaanxi Huike Plant Development Co., Ltd., Product No.: HK3630; Unless otherwise specified, all other materials and reagents used in the examples are commercially available.

[0021] Examples 1-6 and Comparative Examples 1-7 The components and their weight parts of the sensitive skin redness-relieving and soothing compositions of Examples 1-6 and Comparative Examples 1-7 are shown in Table 1. The total weight of each composition is the same.

[0022] Table 1

[0023] The soothing compositions of Examples 1-6 and Comparative Examples 1-7 were prepared by mixing the components evenly to obtain the soothing compositions.

[0024] Comparative Example 8 The only difference between Comparative Example 8 and Example 1 is that Comparative Example 8 uses fructooligosaccharides instead of stachyose.

[0025] Comparative Example 9 The only difference between Comparative Example 9 and Example 1 is that Comparative Example 9 uses mussel adhesive protein instead of silk fibroin.

[0026] Comparative Example 10 The only difference between Comparative Example 10 and Example 1 is that Comparative Example 10 uses aminomethylpropanol instead of 4-tert-butylcyclohexanol.

[0027] Comparative Example 11 The only difference between Comparative Example 11 and Example 1 is that Comparative Example 11 uses glycerol instead of glycerol glucoside.

[0028] Comparative Example 12 The only difference between Comparative Example 12 and Example 1 is that Comparative Example 12 uses grape seed extract instead of flax seed extract.

[0029] Test Example 1: Cell experiments demonstrated that the composition has a redness-reducing effect. This test case investigates the redness-reducing effects of the soothing compositions prepared in Examples 1-6 and Comparative Examples 1-12.

[0030] Experimental Methods: The cell line used was human skin capillary endothelial cells (Beina Biotechnology). The test conditions were: incubator temperature 37±1℃, saturated humidity, and carbon dioxide 5±1%. Cells were cultured and treated according to groups, followed by testing. The specific test was the determination of vascular endothelial growth factor (VEGF) content, and the test method is as follows: (1) The cell suspension was seeded into a 96-well cell culture plate at a density of 2000 cells / well. 100 μL of HDMEC cell culture medium (Beina Biotechnology) was added to each well and cultured for 24 h. (2) Discard the supernatant, add 100 μL of culture medium to the blank group, and add 100 μL of culture medium containing 0.1 wt% of the corresponding sample (Examples 1-6 and Comparative Examples 1-12) to the sample group, and incubate for 24 h; (3) Collect cells separately, wash 3 times with PBS buffer, add 50 μL of RIPA cell lysis buffer containing protease inhibitor to each well, centrifuge the lysed sample at 12000g for 5 minutes, and take the supernatant. (4) Determination of vascular endothelial growth factor (VEGF) content: The VEGF content in the cell supernatant of each group was detected using a human vascular endothelial growth factor A (VEGF-A) ELISA kit (catalog number BLL108277E, Baililai Biotechnology); the reduction rate of VEGF in each example and comparative example was calculated using the following formula: VEGF reduction rate (%) = (VEGF content) 空白组 -VEGF content 样品组 ) / VEGF content 空白组 ×100%, where a higher VEGF reduction rate indicates a stronger ability of the composition to inhibit blood vessels and a better redness-reducing effect. The results are shown in Table 2.

[0031] Test Example 2: Cell experiments demonstrated that the composition has a soothing effect. This study investigates the soothing effects of the soothing compositions prepared in Examples 1-6 and Comparative Examples 1-12: Experimental methods: The cell line used was mouse mononuclear macrophage leukemia cell line RAW264.7 (Wuhan Pronosei Life Science Technology Co., Ltd.). The test conditions were: incubator temperature 37±1℃, saturated humidity, and carbon dioxide 5±1%. Cells were cultured and treated according to groups, followed by testing. The specific test was the detection of the inflammatory factor IL-6, and the test method is as follows: (1) Seed the cell suspension into 12-well cell culture plates at a density of 5 × 10⁶ cells per well. 4 Add 100 μL of DMEM medium (2105341, Gibco) to each well and incubate for 24 h; (2) Discard the liquid in the wells. Add 100 μL of DMEM medium containing 1 μg / mL lipopolysaccharide (LPS) to the control group. Add 100 μL of DMEM medium containing 1 μg / mL lipopolysaccharide (LPS) and 0.1 wt% of the corresponding samples (Examples 1-6 and Comparative Examples 1-12) to the sample groups respectively. Set up 6 parallel replicates in each group and continue to culture for 24 h. (3) Detection of inflammatory factor IL-6 content: The content of inflammatory factor IL-6 released by cells in culture medium was detected using a human IL-6 ELISA kit (catalog number EHC007.96, Shenzhen Xinbosheng Biotechnology Co., Ltd.). The specific operation was to take equal amounts of supernatant and add them to the corresponding reaction wells of the kit. After incubation, washing, and color development, the absorbance OD value was measured at a specific wavelength using an ELISA reader. The content of inflammatory factor IL-6 in each group was calculated according to the standard curve.

[0032] Interleukin-6 (IL-6) is a key pro-inflammatory cytokine. Abnormally elevated levels in the skin can trigger a series of negative effects: it directly promotes acute-phase reactions and persistent inflammation, recruiting more immune cells to infiltrate; at the same time, it disrupts the skin barrier function, inhibits keratinocyte differentiation, and reduces the expression of key barrier proteins, ultimately leading to problems such as skin sensitivity and redness.

[0033] The soothing effect of the composition is expressed by the improvement of the inflammatory factor IL-6, as shown in the following formula: IL-6 improvement rate / % = (1 - IL-6 content) 样品组 / IL-6 content 对照组 ()×100%; The higher the IL-6 improvement rate, the better the soothing ability of the composition. The results are shown in Table 2.

[0034] Table 2. VEGF reduction rate and IL-6 improvement rate in each group Group VEGF reduction rate / % IL-6 improvement rate / % Example 1 57.3 51.2 Example 2 57.7 51.6 Example 3 48.3 47.8 Example 4 45.4 44.9 Example 5 39.8 30.2 Example 6 37.1 36.5 Comparative Example 1 23.6 21.9 Comparative Example 2 22.3 20.4 Comparative Example 3 13.6 14.2 Comparative Example 4 20.9 23.5 Comparative Example 5 11.2 19.8 Comparative Example 6 20.4 21.0 Comparative Example 7 14.7 15.4 Comparative Example 8 16.2 16.9 Comparative Example 9 24.0 26.7 Comparative Example 10 11.4 20.4 Comparative Example 11 24.0 22.1 Comparative Example 12 16.1 18.5 As shown in Table 2, and combining the data from Examples 1-6 and Comparative Examples 1-2, when the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol, and flaxseed extract is not within the range of (0.5-8):(0.01-2):(0.01-1):(0.01-1):(0.01-1), the soothing and redness-reducing effects of the composition will decrease significantly. However, when the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol, and flaxseed extract is within the range of (2-3):(0.3-0.5):(0.2-0.3):(0.1-0.2):(0.1-0.2), the soothing and redness-reducing effects of the composition are at a better level.

[0035] Based on the data from Example 1 and Comparative Examples 3-12, it can be seen that the soothing and redness-reducing effects of the compositions in Comparative Examples 3-12 are lower than those in Example 1. This indicates that stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol, and flaxseed extract can synergistically improve the soothing and redness-reducing effects of the compositions.

[0036] Application Example 1-8 and Comparative Application Example 1-13 The present invention provides an application example and a comparative application example of a lotion with soothing and repairing effects. The components (mass percentage) of the lotion are shown in Table 3. The soothing compositions used in application examples 1-6 are the soothing compositions prepared in examples 1-6, and the soothing compositions used in application examples 7-8 are the soothing compositions prepared in example 1. The soothing compositions used in comparative application examples 1-12 are the soothing compositions prepared in comparative examples 1-12. A comparative application example 13 (blank application example) is also provided, the only difference between comparative application example 13 and application example 1 being that no soothing composition is added. Table 3. Raw materials and their mass percentage of emulsions with soothing and repairing effects.

[0037] The preparation method of the above-mentioned lotion with soothing and repairing effects includes the following steps: (1) Mix the humectant, thickener and EDTA-disodium with deionized water and stir. Heat to 85°C and homogenize at 1300 rpm for 4 min. After homogenization, keep warm for later use to obtain phase A. (2) Mix the oil phase, heat to 75°C, homogenize at 1300 rpm for 4 min, keep warm after homogenization, and obtain phase B; (3) Heat phase A to 80°C, add phase B at 300 rpm, stir and mix, then cool to 45°C, add the soothing composition and continue stirring for 8 min, finally add the remaining phase C pH adjuster (arginine) to adjust the pH, then stop stirring, discharge the material and obtain the emulsion.

[0038] Test Example 3: Human Skin Patch Test.

[0039] Sixty volunteers were recruited, 30 men and 30 women, aged 20-50 years, and randomly divided into two groups of 15 men and 15 women each. A closed patch test method was used. Equal volumes (0.020 mL-0.025 mL) of the test sample (emulsions obtained in Application Examples 1-8 and Control Application Examples 1-13) were placed in a specific patch applicator. The patch was then applied to the volunteer's arm with hypoallergenic adhesive tape, gently pressed to ensure even application, and left for 24 hours. The blank control group used distilled water, and the blank application examples used an emulsion without the soothing composition. One patch applicator was applied to each arm of each volunteer. Each patch applicator had 10 holes, allowing each volunteer (both arms) to test 20 samples simultaneously. The test samples for the first group were the emulsions prepared in Application Examples 1-8 and Control Application Example 13 (blank application example), and the test samples for the second group were the emulsions prepared in Control Application Examples 1-12 and the blank application example. A blank control was included in each group. After 24 hours, the patch applicator was removed, and skin reactions were observed and recorded at 0.5 hours, 24 hours, and 48 hours. The severity of adverse skin reactions is shown in Table 4 below.

[0040] Table 4 Adverse Reaction Levels Rating levels Skin reaction 0 negative reaction 1 Suspicious reaction, only slight erythema 2 Weak positive reaction (erythema reaction): erythema, infiltration, edema, and papules may be present. 3 Strong positive reaction (herpes reaction): erythema, infiltration, edema, papules; the reaction may extend beyond the test area. 4 Extremely strong positive reaction (confluent herpes simplex reaction): obvious erythema, severe infiltration, edema, confluent herpes simplex; reaction extends beyond the test area. After testing, the lotions provided in Application Examples 1-8, Comparative Application Examples 1-12, and Blank Application Examples of the present invention all showed negative reactions after human patch testing, indicating that they are safe and non-irritating to human skin.

[0041] Test Example 4: Human efficacy test of the composition in moisturizing, soothing and reducing redness. Experimental Methods: 126 Asian adult participants aged 18-60 years who reported sensitive and red skin were randomly divided into 21 groups of 6 participants each. Volunteers applied the sample (prepared from Application Examples 1-8, Control Application Examples 1-12, and the blank application example) to their entire face twice daily, morning and evening. Applications were made before application (T0) and 30 minutes after application (T2). 30min ) and after 7 days of use (T) 7d Data were collected separately. After arriving at the site, volunteers washed their faces with facial cleanser and sat quietly for 30 minutes in an air-conditioned room with a temperature of 21±1℃ and humidity of 50±10%. Researchers then used a Corneometer probe to measure the skin moisture content of the cheekbones. A Visia-7 was used to photograph the volunteers' faces, and image analysis was performed on the exported red area images to obtain the a* value. After the volunteers used the sample for the first time in the air-conditioned room, they sat quietly for another 30 minutes, and their skin moisture content and a* value were measured using the corresponding instruments.

[0042] Skin moisturizing ability is represented by the improvement rate of skin moisture content; the higher the improvement rate, the better the skin moisturizing ability. Skin soothing and redness-reducing ability is represented by the improvement rate of a* value; the higher the improvement rate of a* value, the better the soothing and redness-reducing effect. The formulas for the improvement rate of skin moisture content and the improvement rate of a* value are as follows: Skin moisture content improvement rate = (skin moisture content) T30min / T7d -Skin moisture content T0 ) / Skin moisture content T0 ×100%.

[0043] a* value improvement rate = (a* value) T0 -a* value T30min / T7d ) / a*value T0 ×100%.

[0044] The results were averaged, as shown in Table 5.

[0045] Table 5. Human efficacy data for each group of emulsions

[0046] As shown in Table 5, each emulsion showed improved moisturizing and soothing redness-reducing effects compared to the control application example 13 (blank application example without added composition).

[0047] Combining the data from Application Examples 1-6 and Comparative Application Examples 1-2, it can be seen that when the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol, and flaxseed extract is not within the range of (0.5-8):(0.01-2):(0.01-1):(0.01-1):(0.01-1), the moisturizing and soothing redness-reducing effects of the emulsion will significantly decrease. However, when the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol, and flaxseed extract is within the range of (2-3):(0.3-0.5):(0.2-0.3):(0.1-0.2):(0.1-0.2), the moisturizing and soothing redness-reducing effects of the emulsion are at a relatively optimal level.

[0048] Combining the data from Application Example 1 and Comparative Application Examples 3-12, it can be seen that the moisturizing and soothing redness-reducing effects of the composition in Comparative Application Examples 3-12 are lower than those in Example 1. This indicates that stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract can synergistically improve the moisturizing and soothing redness-reducing effects of the emulsion.

[0049] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A soothing composition for sensitive skin that reduces redness, characterized in that, It comprises the following components: stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract, wherein the weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract is (0.5-8):(0.01-2):(0.01-1):(0.01-1):(0.01-1).

2. The sensitive skin redness-reducing and soothing composition as described in claim 1, characterized in that, The weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract is (1-5):(0.1-1):(0.1-0.5):(0.05-0.5):(0.05-0.5).

3. The sensitive skin redness-reducing and soothing composition as described in claim 1, characterized in that, The weight ratio of stachyose, silk fibroin, glyceryl glucoside, 4-tert-butylcyclohexanol and flaxseed extract is (2-3):(0.3-0.5):(0.2-0.3):(0.1-0.2):(0.1-0.2).

4. The use of the sensitive skin redness-reducing and soothing composition according to any one of claims 1-3 in the preparation of cosmetics.

5. The application of the sensitive skin redness-reducing and soothing composition as described in claim 4 in the preparation of cosmetics, characterized in that, The cosmetic is a toner, lotion, cream, mask, serum, or spray, and the amount of the composition added is 1%-5% of the total weight of the cosmetic.

6. A lotion with soothing and repairing effects, characterized in that, The ingredients comprise the following ingredients by weight percentage: 1%-5% of the sensitive skin redness-reducing and soothing composition according to any one of claims 1-3, 0.1%-0.3% of thickener, 0.5%-2.5% of moisturizer, 3-5% of oil phase and 0.01%-0.3% of pH adjuster, with the balance being deionized water.

7. The emulsion as described in claim 6, characterized in that, The raw material is selected from at least one of (a)-(d): (a) The thickener comprises at least one of xanthan gum, carbomer, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer and ammonium acryloyl dimethyl taurate / VP copolymer; (b) The moisturizing agent comprises at least one of allantoin, hydrogenated lecithin, betaine, β-glucan, trehalose, caprylyl glycol, dipropylene glycol, sodium hyaluronate, 1,2-butanediol and glycerin; (c) The oil phase is a composition of C14-22 alcohol, C12-20 alkyl glucoside, and caprylic / capric triglyceride; (d) The pH adjuster includes at least one of arginine, sodium hydroxide and EDTA-disodium.

8. The method for preparing the emulsion according to claim 7, characterized in that, Includes the following steps: S1. Mix the humectant, thickener, deionized water and part of the pH adjuster, and homogenize at 75-85℃ to obtain phase A; S2. Heat the oil phase to 70-80℃ and homogenize it to obtain phase B; S3. Heat phase A to 75-85℃ and mix it with phase B. When the system temperature drops to 35-45℃, add each component of the sensitive skin redness relief and soothing composition and stir evenly. Finally, add the remaining pH adjuster to adjust the pH to obtain the emulsion.

Images